GSK Annual CFF
-$7.02 B
-$8.04 B-788.73%
31 December 2023
Summary:
As of January 22, 2025, GSK annual cash flow from financing activities is -$7.02 billion, with the most recent change of -$8.04 billion (-788.73%) on December 31, 2023. During the last 3 years, it has risen by +$5.98 billion (+46.02%). GSK annual CFF is now -221.64% below its all-time high of $5.77 billion, reached on December 31, 1995.GSK Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GSK Quarterly CFF
-$1.72 B
+$273.36 M+13.73%
30 September 2024
Summary:
As of January 22, 2025, GSK quarterly cash flow from financing activities is -$1.72 billion, with the most recent change of +$273.36 million (+13.73%) on September 30, 2024. Over the past year, it has increased by +$2.71 billion (+61.17%). GSK quarterly CFF is now -116.06% below its all-time high of $10.70 billion, reached on March 31, 2022.GSK Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GSK TTM CFF
-$9.48 B
+$517.28 M+5.17%
30 September 2024
Summary:
As of January 22, 2025, GSK TTM cash flow from financing activities is -$9.48 billion, with the most recent change of +$517.28 million (+5.17%) on September 30, 2024. Over the past year, it has dropped by -$2.46 billion (-35.04%). GSK TTM CFF is now -540.16% below its all-time high of $2.15 billion, reached on March 31, 2022.GSK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GSK Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -788.7% | +61.2% | -35.0% |
| 3 y3 years | +46.0% | -116.1% | -540.2% |
| 5 y5 years | +17.7% | -116.1% | -540.2% |
GSK Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -788.7% | +32.8% | -116.1% | +72.8% | -540.2% | +9.2% |
| 5 y | 5-year | -788.7% | +46.0% | -116.1% | +72.8% | -540.2% | +31.1% |
| alltime | all time | -221.6% | +46.0% | -116.1% | +72.8% | -540.2% | +31.1% |
GSK Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.72 B(-13.7%) | -$9.48 B(-5.2%) |
| June 2024 | - | -$1.99 B(+48.1%) | -$10.00 B(+25.3%) |
| Mar 2024 | - | -$1.34 B(-69.6%) | -$7.98 B(+13.6%) |
| Dec 2023 | -$7.02 B(-788.7%) | -$4.42 B(+97.9%) | -$7.02 B(+70.4%) |
| Sept 2023 | - | -$2.24 B(-8288.3%) | -$4.12 B(+10.6%) |
| June 2023 | - | $27.30 M(-107.1%) | -$3.72 B(-63.0%) |
| Mar 2023 | - | -$386.53 M(-74.6%) | -$10.06 B(-1087.5%) |
| Dec 2022 | $1.02 B(-109.8%) | -$1.52 B(-17.2%) | $1.02 B(-181.0%) |
| Sept 2022 | - | -$1.84 B(-70.8%) | -$1.26 B(-1.3%) |
| June 2022 | - | -$6.31 B(-159.0%) | -$1.28 B(-159.2%) |
| Mar 2022 | - | $10.70 B(-381.4%) | $2.15 B(-120.6%) |
| Dec 2021 | -$10.44 B(-19.7%) | -$3.80 B(+104.7%) | -$10.44 B(+11.5%) |
| Sept 2021 | - | -$1.86 B(-35.6%) | -$9.36 B(-29.2%) |
| June 2021 | - | -$2.88 B(+52.1%) | -$13.22 B(-2.4%) |
| Mar 2021 | - | -$1.90 B(-30.3%) | -$13.55 B(+4.2%) |
| Dec 2020 | -$13.00 B(+453.5%) | -$2.72 B(-52.4%) | -$13.00 B(-5.5%) |
| Sept 2020 | - | -$5.72 B(+77.8%) | -$13.76 B(+31.4%) |
| June 2020 | - | -$3.22 B(+138.5%) | -$10.47 B(+23.7%) |
| Mar 2020 | - | -$1.35 B(-61.3%) | -$8.47 B(+260.4%) |
| Dec 2019 | -$2.35 B(-72.4%) | -$3.48 B(+43.5%) | -$2.35 B(-28.8%) |
| Sept 2019 | - | -$2.43 B(+100.4%) | -$3.30 B(+11.5%) |
| June 2019 | - | -$1.21 B(-125.4%) | -$2.96 B(-12.0%) |
| Mar 2019 | - | $4.77 B(-207.7%) | -$3.36 B(-60.6%) |
| Dec 2018 | -$8.52 B(+3.5%) | -$4.43 B(+112.3%) | -$8.52 B(+3.4%) |
| Sept 2018 | - | -$2.09 B(+29.3%) | -$8.24 B(+16.4%) |
| June 2018 | - | -$1.61 B(+310.1%) | -$7.08 B(+4.7%) |
| Mar 2018 | - | -$393.51 M(-90.5%) | -$6.76 B(-17.9%) |
| Dec 2017 | -$8.24 B(-4.9%) | -$4.15 B(+348.4%) | -$8.24 B(+19.3%) |
| Sept 2017 | - | -$925.52 M(-28.5%) | -$6.90 B(-16.4%) |
| June 2017 | - | -$1.29 B(-30.8%) | -$8.26 B(-4.6%) |
| Mar 2017 | - | -$1.87 B(-33.6%) | -$8.65 B(-0.1%) |
| Dec 2016 | -$8.66 B(-20.2%) | -$2.82 B(+23.8%) | -$8.66 B(+20.5%) |
| Sept 2016 | - | -$2.28 B(+34.8%) | -$7.19 B(-11.3%) |
| June 2016 | - | -$1.69 B(-10.2%) | -$8.11 B(-19.2%) |
| Mar 2016 | - | -$1.88 B(+39.7%) | -$10.03 B(-7.6%) |
| Dec 2015 | -$10.86 B(+22.3%) | -$1.35 B(-57.9%) | -$10.86 B(-10.8%) |
| Sept 2015 | - | -$3.20 B(-11.5%) | -$12.17 B(+31.9%) |
| June 2015 | - | -$3.61 B(+33.8%) | -$9.23 B(+26.5%) |
| Mar 2015 | - | -$2.70 B(+1.5%) | -$7.29 B(-17.8%) |
| Dec 2014 | -$8.88 B(-9.6%) | -$2.66 B(+950.8%) | -$8.88 B(+0.8%) |
| Sept 2014 | - | -$253.37 M(-84.9%) | -$8.81 B(-14.6%) |
| June 2014 | - | -$1.68 B(-60.9%) | -$10.32 B(-12.8%) |
| Mar 2014 | - | -$4.28 B(+65.1%) | -$11.84 B(+20.6%) |
| Dec 2013 | -$9.81 B(+84.8%) | -$2.59 B(+47.2%) | -$9.81 B(+11.2%) |
| Sept 2013 | - | -$1.76 B(-44.9%) | -$8.82 B(-1.6%) |
| June 2013 | - | -$3.20 B(+41.5%) | -$8.97 B(+59.8%) |
| Mar 2013 | - | -$2.26 B(+41.0%) | -$5.61 B(+5.7%) |
| Dec 2012 | -$5.31 B(-46.9%) | -$1.60 B(-16.1%) | -$5.31 B(-7.6%) |
| Sept 2012 | - | -$1.91 B(-1302.0%) | -$5.75 B(-15.0%) |
| June 2012 | - | $158.84 M(-108.1%) | -$6.76 B(-31.4%) |
| Mar 2012 | - | -$1.96 B(-4.0%) | -$9.85 B(-1.4%) |
| Dec 2011 | -$9.99 B | -$2.04 B(-30.2%) | -$9.99 B(+5.3%) |
| Sept 2011 | - | -$2.92 B(-0.4%) | -$9.49 B(+16.5%) |
| June 2011 | - | -$2.93 B(+39.7%) | -$8.15 B(-0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2011 | - | -$2.10 B(+36.5%) | -$8.17 B(-4.9%) |
| Dec 2010 | -$8.59 B(+97.7%) | -$1.54 B(-2.4%) | -$8.59 B(-4.3%) |
| Sept 2010 | - | -$1.58 B(-46.6%) | -$8.97 B(+63.7%) |
| June 2010 | - | -$2.95 B(+17.1%) | -$5.48 B(-7.5%) |
| Mar 2010 | - | -$2.52 B(+31.2%) | -$5.93 B(+36.4%) |
| Dec 2009 | -$4.35 B(-52.1%) | -$1.92 B(-200.3%) | -$4.35 B(-14.8%) |
| Sept 2009 | - | $1.92 B(-156.4%) | -$5.10 B(-51.9%) |
| June 2009 | - | -$3.40 B(+261.6%) | -$10.61 B(+137.9%) |
| Mar 2009 | - | -$939.94 M(-64.9%) | -$4.46 B(-50.9%) |
| Dec 2008 | -$9.08 B(+160.3%) | -$2.68 B(-25.3%) | -$9.08 B(+170.4%) |
| Sept 2008 | - | -$3.59 B(-230.5%) | -$3.36 B(+12.0%) |
| June 2008 | - | $2.75 B(-149.5%) | -$3.00 B(-61.4%) |
| Mar 2008 | - | -$5.56 B(-282.8%) | -$7.77 B(+122.7%) |
| Dec 2007 | -$3.49 B(-60.5%) | $3.04 B(-194.2%) | -$3.49 B(-60.4%) |
| Sept 2007 | - | -$3.23 B(+59.7%) | -$8.81 B(+24.1%) |
| June 2007 | - | -$2.02 B(+58.2%) | -$7.10 B(-13.5%) |
| Mar 2007 | - | -$1.28 B(-44.0%) | -$8.21 B(-7.1%) |
| Dec 2006 | -$8.83 B(+66.6%) | -$2.28 B(+50.1%) | -$8.83 B(+3.2%) |
| Sept 2006 | - | -$1.52 B(-51.4%) | -$8.56 B(-15.7%) |
| June 2006 | - | -$3.13 B(+64.4%) | -$10.15 B(+100.5%) |
| Mar 2006 | - | -$1.90 B(-5.1%) | -$5.06 B(-4.5%) |
| Dec 2005 | -$5.30 B(-15.1%) | -$2.01 B(-35.6%) | -$5.30 B(+30.8%) |
| Sept 2005 | - | -$3.11 B(-258.9%) | -$4.05 B(-35.1%) |
| June 2005 | - | $1.96 B(-191.6%) | -$6.25 B(+5.0%) |
| Mar 2005 | - | -$2.14 B(+182.4%) | -$5.95 B(-4.7%) |
| Dec 2004 | -$6.24 B(-3.1%) | -$757.90 M(-85.7%) | -$6.24 B(-42.2%) |
| Sept 2004 | - | -$5.31 B(-334.9%) | -$10.80 B(+78.1%) |
| June 2004 | - | $2.26 B(-192.9%) | -$6.06 B(-21.9%) |
| Mar 2004 | - | -$2.43 B(-54.2%) | -$7.76 B(+20.4%) |
| Dec 2003 | -$6.44 B(+173.6%) | -$5.31 B(+824.8%) | -$6.44 B(+1158.7%) |
| Sept 2003 | - | -$574.53 M(-202.4%) | -$511.92 M(-22.6%) |
| June 2003 | - | $561.26 M(-150.3%) | -$661.45 M(-75.7%) |
| Mar 2003 | - | -$1.12 B(-280.7%) | -$2.72 B(+15.4%) |
| Dec 2002 | -$2.35 B(-41.2%) | $618.24 M(-185.4%) | -$2.35 B(-65.0%) |
| Sept 2002 | - | -$724.05 M(-51.6%) | -$6.73 B(+15.6%) |
| June 2002 | - | -$1.49 B(+98.1%) | -$5.82 B(+37.1%) |
| Mar 2002 | - | -$754.53 M(-79.9%) | -$4.25 B(+6.0%) |
| Dec 2001 | -$4.01 B(+384.0%) | -$3.76 B(-2150.4%) | -$4.01 B(+271.7%) |
| Sept 2001 | - | $183.17 M(+123.4%) | -$1.08 B(-15.7%) |
| June 2001 | - | $82.00 M(-115.9%) | -$1.28 B(-8.7%) |
| Mar 2001 | - | -$515.40 M(-37.7%) | -$1.40 B(+69.1%) |
| Dec 2000 | -$827.58 M(-246.1%) | -$827.58 M(+4812.2%) | -$827.58 M(<-9900.0%) |
| Sept 2000 | - | -$16.85 M(-57.2%) | $100.00(-100.0%) |
| June 2000 | - | -$39.35 M(-170.0%) | $16.85 M(-70.0%) |
| Mar 2000 | - | $56.19 M | $56.19 M |
| Dec 1999 | $566.34 M(+0.8%) | - | - |
| Dec 1998 | $561.86 M(-681.3%) | - | - |
| Dec 1997 | -$96.66 M(-90.6%) | - | - |
| Dec 1996 | -$1.03 B(-117.8%) | - | - |
| Dec 1995 | $5.77 B(+67.4%) | - | - |
| June 1995 | $3.45 B(+5807.0%) | - | - |
| June 1994 | $58.37 M(-62.6%) | - | - |
| June 1993 | $156.04 M(-119.0%) | - | - |
| June 1992 | -$819.74 M(-193.4%) | - | - |
| June 1991 | $877.65 M | - | - |
FAQ
- What is GSK annual cash flow from financing activities?
- What is the all time high annual CFF for GSK?
- What is GSK annual CFF year-on-year change?
- What is GSK quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for GSK?
- What is GSK quarterly CFF year-on-year change?
- What is GSK TTM cash flow from financing activities?
- What is the all time high TTM CFF for GSK?
- What is GSK TTM CFF year-on-year change?
What is GSK annual cash flow from financing activities?
The current annual CFF of GSK is -$7.02 B
What is the all time high annual CFF for GSK?
GSK all-time high annual cash flow from financing activities is $5.77 B
What is GSK annual CFF year-on-year change?
Over the past year, GSK annual cash flow from financing activities has changed by -$8.04 B (-788.73%)
What is GSK quarterly cash flow from financing activities?
The current quarterly CFF of GSK is -$1.72 B
What is the all time high quarterly CFF for GSK?
GSK all-time high quarterly cash flow from financing activities is $10.70 B
What is GSK quarterly CFF year-on-year change?
Over the past year, GSK quarterly cash flow from financing activities has changed by +$2.71 B (+61.17%)
What is GSK TTM cash flow from financing activities?
The current TTM CFF of GSK is -$9.48 B
What is the all time high TTM CFF for GSK?
GSK all-time high TTM cash flow from financing activities is $2.15 B
What is GSK TTM CFF year-on-year change?
Over the past year, GSK TTM cash flow from financing activities has changed by -$2.46 B (-35.04%)